US20070280902A1 - Method for treating eye disease or conditions affecting the posterior segment of the eye - Google Patents
Method for treating eye disease or conditions affecting the posterior segment of the eye Download PDFInfo
- Publication number
- US20070280902A1 US20070280902A1 US11/444,349 US44434906A US2007280902A1 US 20070280902 A1 US20070280902 A1 US 20070280902A1 US 44434906 A US44434906 A US 44434906A US 2007280902 A1 US2007280902 A1 US 2007280902A1
- Authority
- US
- United States
- Prior art keywords
- prodrug
- months
- growth factor
- drug
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention involves the fields of ophthalmology, more precisely the treatment of eye disease or conditions, especially disease or condition affecting the posterior segment of the eye.
- the present invention relates to a method for in-vivo sustained release of an active agent through intraocular invasive delivery of a prodrug thereof.
- Treatment of diseases or conditions affecting the posterior segment of the eye are complicated by the inaccessibility of the posterior eye to topically applied medications.
- Treatments of posterior eye diseases require intravitreal or periocular injections or systemic drug administration.
- Local injections are usually preferred to systemic drug administration because the blood/retinal barrier impedes the passage of most drugs from the systemically circulating blood to the interior of the eye. Therefore large systemic doses are needed to treat eye posterior diseases, which often result in systemic toxicities.
- US20050244469 discloses a method for treating an ocular condition comprising the insertion of an implant into an ocular site of a patient with an ocular condition, more preferably in the vitreous body of the eye of a patient to treat a condition or disease of the posterior segment of the eye.
- a recognized advantage of providing a method for an extended treatment is to prevent recurrence of the inflammatory or other posterior ocular condition treated. It can also minimize the number of surgical interventions required by the patient over time to treat an ocular condition.
- the invention relates to the use of prodrug for the manufacture of a medicament or an ophthalmic composition useful for treating an ocular disease affecting the posterior segment of the eye, in a subject in need thereof, wherein the prodrug is a composition injected into the vitreous body, and the frequency of injections does not exceed one injection per month, preferably the frequency of injection is once every two months, more preferably once every six months or more.
- the invention also relates to the use of a prodrug for providing extended duration of treatment of an ocular disease affecting the posterior segment of the eye, in a subject in need thereof, said use comprising administering an amount of a prodrug enabling the sustained release of a therapeutically amount of said drug for a duration of at least one month, preferably at least 2 month, more preferably at least six months.
- no drug can be detected in the vitreous or the molar ratio of the prodrug to the drug, in the vitreous, two months after one single injection of said prodrug, is more than 60.
- the molar ratio of the prodrug to the drug, in the retina, two months after one single injection of said prodrug is less than 60.
- the molar ratio of the prodrug to the drug, in the choroid, two months after one single injection of said prodrug is less than 60.
- the molar ratio of the prodrug to the drug, in the vitreous, two months after one injection of said prodrug is more than 60 and the molar ratio of the prodrug to the drug, in the retina and/or in the choroid, two months after one injection of said prodrug, is less than 60.
- the prodrug is injected in the vitreous in an amount enabling the sustained release of a therapeutically amount of said drug for a duration of at least one month, preferably at least 2 months, more preferably at least 6 months.
- the prodrug is injected with a frequency of one injection every two months.
- the release of the prodrug and its transformation into the drug is such that a therapeutic amount of drug is present on the target site, for example retina or choroid, during two months, the prodrug being sustaineously released during this period of time.
- the prodrug is injected with a frequency of one injection every six months.
- the prodrug is within a composition, wherein said prodrug is in combination with any suitable excipient or carrier for ophthalmic use.
- the carrier is oily.
- suitable oily carrier are mineral oils such as silicone, paraffin or vegetal oils such as medium chain triglycerides, castor oil, olive oil, corn oil, palm oil or any other oil suitable for intraocular injection.
- the carrier is an emulsion, preferably an oil-in-water emulsion, more preferably an anionic emulsion.
- said emulsion comprises colloid particles having an oily core surrounded by interfacial film, the film comprising surface active agents, lipids or both, at least part or the surface active agents or lipids in the interfacial film having negatively charged polar groups, and the colloid particles have a negative zeta potential.
- the prodrug is comprised within the emulsion in an amount of about 0.01% to about 10% w/w of the composition.
- the prodrug is comprised in the amount of about 0.5% to about 3% w/w of the composition. In a preferred embodiment, the prodrug is comprised in an amount of about 2% w/w of the composition. In another preferred embodiment of the present invention, the prodrug is comprised in an amount of about 1% w/w of the composition.
- the Applicant performed a number of tests and noticed that the invention had the further advantage that he could not detect any release of drug in the plasma, which may mean that there is none or few passage of the drug released through the general system of the subject, and in any event, no related side effect is observed.
- injecting in the vitreous body means performing an intravitreal injection.
- the hydrolysis of the prodrug results in therapeutically amounts of drug at the targeted site of action, preferably at retina and/or choroid.
- the half-life of the prodrug in the target tissue is of at least 15 days, preferably of at least 30 days, preferably of at least 60 days, preferably of at least 6 months.
- the present invention intends to propose solutions for treating various ophthalmic or ocular conditions and diseases.
- the present invention is especially designed for the treatment of posterior ocular conditions, which means any disease, ailment or condition which primarily affects or involves a posterior ocular site such as choroid or sclera (in a position posterior to a plane through the posterior wall of the lens capsule), vitreous, vitreous chamber, retina, optic nerve (including the optic disc), and blood vessels and nerves which vascularize or innervate a posterior ocular site.
- a posterior ocular condition can include a disease, ailment or condition.
- Macular Disorders such as myopia, Non-Exudative Age Related Macular Degeneration (Dry), Exudative Age Related Macular Degeneration (Wet), Choroidal Neovascular Membranes (others than ARMD) and Cystoid Macular Edema
- Inflammatory Disorders such as Uveitic Retinal Disease, Endophthalmitis, Toxoplasmic Retinochoroiditis, Systemic General Disorders Associated with Retinal Uveitis or Retinochoroidal Syndromes (Syphilis, Tuberculosis, Lyme Diseases, Chung Strauss Disease, LED, etc), Neuroretinitis, Optic Neuritis
- Vascular Disorders such as Diabetic Retinopathy (all stages), Diabetic Macular Edema, Arterial Occlusion, Venous Occlusion; Heredo Retinal Dystrophies such as Stargardt's Disease, Fundus Flavimaculatus, other Heredomacular Dysropy; Trauma caused by
- an effective amount may be used interchangeably and refer to an amount of an ingredient which is sufficient to achieve an intended physiological effect.
- a “therapeutically effective amount” refers to a non-toxic, but sufficient amount of an active agent, to achieve therapeutic results in treating a condition for which the active agent is known to be effective. The determination of an effective amount is well within the ordinary skill in the art of pharmaceutical sciences and medicine, in that it may depend on various biological factors or individual variation and response to treatments.
- subject refers to a mammal that may benefit from the administration of a composition or method as recited herein. Most often, the subject will be a human but can be of any animals.
- administering refers to the manner in which a prodrug is presented to a subject.
- invasive refers to a form of administration that ruptures or punctures a biological membrane or structure with a mechanical means across which a prodrug is being delivered.
- active agent or “drug” may be used interchangeably to refer to an agent or substance that has measurable specified or selected physiologic activity when administered to a subject in a significant or effective amount.
- drugs useful in the present invention include without limitation: antivirals, chosen from the group comprising idoxuridine, trifluorothymidine, trifluorouridine, acyclovir, ganciclovir, cidofovir, interferon, DDI, AZT, foscamet, vidarabine, irbavirin; non-steroidal anti-inflammatories chosen from the group comprising amfenac, ketorolac, indomethacin, ibuprofen, diclofenac, flurbiprofen, piroxicam and other COX2 inhibitors; cytokines, interleukines and growth factors epidermal growth factor, fibroblast growth factor, pigment epithelium growth factor, platelet derived growth factor, transforming growth factor beta, cili
- the drug has an ophthalmic physiologic therapeutic activity, whereas the prodrug is inactive.
- the prodrug is a drug, or is prepared from a drug, which has or was grafted with functional groups such as haloformyl, hydroxyl, aldehyde, alkyl, alkenyl, alkynyl, carboxamide, primary amine, secondary amine, tertiary amine, quaternary ammonium ion, azo (Diimide), benzyl, carboxylate, carboxyl, cyanate, thiocyanate, ether, ester, halo, primary ketimine, secondary ketimine, primary aldimine, secondary aldimine, isocyanide, isocyanate, isothiocyanate, ketone, nitrile, nitro, nitroso, peroxy, phenyl, phosphino, phosphate, phosphono, phosphate, pyridyl, sulfonyl, sulfo, sulfinyl or
- prodrug refers to a drug precursors which following administration, release the drug in vivo via some chemical or physiological process.
- the prodrug is inactive.
- the prodrug releases the drug by a biological reaction, such as enzymatic cleavage.
- the prodrug is a composition including the pro-active ingredient, eventually in combination with any suitable excipient, especially any excipient injectable in the vitreous body of the eye.
- the term composition should not be construed as an implantable device.
- the enzyme involved in the transformation of the prodrug into the drug may be:
- Transferases transferring one carbon, alkyl, aryl, nitrogenous, aldehyde or ketone groups; transferases; acyltransferases; glycosyltransferases; transferases transferring phosphorus-, selenium- or sulfur-containing groups;
- Lyases such as carbon-carbon, carbon-oxygen, carbon-nitrogen, carbon-sulfur, carbon-halide or phosphorus-oxygen lyases
- Isomerases such as racemases and epimerases; intramolecular oxidoreductases; intramolecular transferases or intramolecular lyases;
- Preferred enzymes are hydrolases which act on ester or ether bonds; hydrolases acting on carbon-nitrogen, carbon-carbon, halide, phosphorus-nitrogen, sulfur-nitrogen, carbon-phosphorus, sulfur-sulfur or carbon-sulfur bonds; glycosylases; peptidases; hydrolases acting on acid anhydrides.
- Preferred prodrugs are esters of drugs, wherein the ester group is of formula —COOR, or ether of drugs wherein the ester group is of formula OR, wherein R is a long alkyl chain, preferably a C4-C16 alkyl chain, more preferably any suitable lipophilic chain.
- alkyl means straight chain saturated hydrocarbon or branched saturated hydrocarbon.
- Preferred alkyl groups are those comprising more than 4 carbon atoms, preferentially more than 8 atoms, more preferentially more than 12 atoms.
- a liquid chromatographic-mass spectrometric method for the simultaneous determination of dexamethasone and dexamethasone palmitate in ocular tissues was developed.
- Analytes and internal standard (roxithromycine) were extracted from the tissues using acetonitrile and separated by reverse phase liquid chromatography with a C8 column and a gradient mobile phase.
- the compounds were detected by mass spectrometric detection (atmospheric pressure ionization) with selected ion monitoring (SIM) (393.0 for dexamethasone and 631.5 for dexamethasone palmitate).
- SIM selected ion monitoring
- the method was selective for both compounds and the limits of quantification were 32.7 ng/g of retina and 71.6 ng/g choroid.
- the unweighed linear model was applied.
- dexamethasone therapeutic levels of about 1000 ng/g were maintained for at least 2 months in the target tissues. Moreover, considerable amounts of the prodrug dexapalmitate remained in both retina and choroid, indicating an even more long-lasting release.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
This invention relates to the use of prodrug for the manufacture of a medicament useful for treating an ocular disease affecting the posterior segment of the eye, in a subject in need thereof, wherein the prodrug is a composition injected into the vitreous body, and the frequency of injections does not exceed one injection per month.
Description
- The present invention involves the fields of ophthalmology, more precisely the treatment of eye disease or conditions, especially disease or condition affecting the posterior segment of the eye.
- The present invention relates to a method for in-vivo sustained release of an active agent through intraocular invasive delivery of a prodrug thereof.
- Treatment of diseases or conditions affecting the posterior segment of the eye are complicated by the inaccessibility of the posterior eye to topically applied medications.
- Treatments of posterior eye diseases require intravitreal or periocular injections or systemic drug administration. Local injections are usually preferred to systemic drug administration because the blood/retinal barrier impedes the passage of most drugs from the systemically circulating blood to the interior of the eye. Therefore large systemic doses are needed to treat eye posterior diseases, which often result in systemic toxicities.
- There are diseases for which periocular injections do not allow the delivery of efficacious amounts to the target sites. For these diseases, intravitreal injections are found necessary. However, the short half-life of most injected compounds in the vitreous, a few hours only, requires frequent administrations.
- Repeated intravitreal injections are responsible of side effects such as retinal detachment or cataract. Moreover, these injections are poorly accepted by patients unable to deal with the pain and discomfort.
- Some research on implant devices has been conducted in order to address this technical problem. For example, US20050244469 discloses a method for treating an ocular condition comprising the insertion of an implant into an ocular site of a patient with an ocular condition, more preferably in the vitreous body of the eye of a patient to treat a condition or disease of the posterior segment of the eye.
- However, there is a need for alternative solutions for providing therapeutic treatment of an ocular condition, such as posterior ocular condition. In particular, there is still a need for treatment over an extended duration, for example, time periods extending up to 30 days, 60 days, 90 days, 120 days, 6 months, 8 months, 12 months or more. There is also a need to reduce the frequency of injections, such that the number of injection should be equal or less than once a month, preferably equal or less than once every 2 months, more preferably equal or less than once every three months, most preferably equal or less than once every four, five or six months.
- A recognized advantage of providing a method for an extended treatment is to prevent recurrence of the inflammatory or other posterior ocular condition treated. It can also minimize the number of surgical interventions required by the patient over time to treat an ocular condition.
- It is a goal of this invention to provide a sustained release of a therapeutically amount of an active agent for an extended duration as described hereabove, with a reduced amount of injections.
- More precisely, the invention relates to the use of prodrug for the manufacture of a medicament or an ophthalmic composition useful for treating an ocular disease affecting the posterior segment of the eye, in a subject in need thereof, wherein the prodrug is a composition injected into the vitreous body, and the frequency of injections does not exceed one injection per month, preferably the frequency of injection is once every two months, more preferably once every six months or more.
- The invention also relates to the use of a prodrug for providing extended duration of treatment of an ocular disease affecting the posterior segment of the eye, in a subject in need thereof, said use comprising administering an amount of a prodrug enabling the sustained release of a therapeutically amount of said drug for a duration of at least one month, preferably at least 2 month, more preferably at least six months.
- According to an embodiment of the invention, no drug can be detected in the vitreous or the molar ratio of the prodrug to the drug, in the vitreous, two months after one single injection of said prodrug, is more than 60.
- According to another embodiment of the invention, the molar ratio of the prodrug to the drug, in the retina, two months after one single injection of said prodrug, is less than 60.
- According to an embodiment of the invention, the molar ratio of the prodrug to the drug, in the choroid, two months after one single injection of said prodrug, is less than 60.
- In a most preferred embodiment, the molar ratio of the prodrug to the drug, in the vitreous, two months after one injection of said prodrug, is more than 60 and the molar ratio of the prodrug to the drug, in the retina and/or in the choroid, two months after one injection of said prodrug, is less than 60.
- Advantageously, the prodrug is injected in the vitreous in an amount enabling the sustained release of a therapeutically amount of said drug for a duration of at least one month, preferably at least 2 months, more preferably at least 6 months.
- According to an embodiment, the prodrug is injected with a frequency of one injection every two months. In this embodiment, the release of the prodrug and its transformation into the drug is such that a therapeutic amount of drug is present on the target site, for example retina or choroid, during two months, the prodrug being sustaineously released during this period of time.
- According to another embodiment of the invention, the prodrug is injected with a frequency of one injection every six months.
- Preferably, the prodrug is within a composition, wherein said prodrug is in combination with any suitable excipient or carrier for ophthalmic use. According to a first embodiment, the carrier is oily. Examples of suitable oily carrier are mineral oils such as silicone, paraffin or vegetal oils such as medium chain triglycerides, castor oil, olive oil, corn oil, palm oil or any other oil suitable for intraocular injection.
- According to another embodiment, the carrier is an emulsion, preferably an oil-in-water emulsion, more preferably an anionic emulsion. In the embodiment where the carrier is an anionic emulsion, it is preferred that said emulsion comprises colloid particles having an oily core surrounded by interfacial film, the film comprising surface active agents, lipids or both, at least part or the surface active agents or lipids in the interfacial film having negatively charged polar groups, and the colloid particles have a negative zeta potential. Preferably, the prodrug is comprised within the emulsion in an amount of about 0.01% to about 10% w/w of the composition. According to an embodiment, the prodrug is comprised in the amount of about 0.5% to about 3% w/w of the composition. In a preferred embodiment, the prodrug is comprised in an amount of about 2% w/w of the composition. In another preferred embodiment of the present invention, the prodrug is comprised in an amount of about 1% w/w of the composition.
- The Applicant performed a number of tests and noticed that the invention had the further advantage that he could not detect any release of drug in the plasma, which may mean that there is none or few passage of the drug released through the general system of the subject, and in any event, no related side effect is observed.
- In the meaning of this invention, injecting in the vitreous body means performing an intravitreal injection.
- According to the invention, the hydrolysis of the prodrug results in therapeutically amounts of drug at the targeted site of action, preferably at retina and/or choroid.
- According to a preferred embodiment of the invention, the half-life of the prodrug in the target tissue is of at least 15 days, preferably of at least 30 days, preferably of at least 60 days, preferably of at least 6 months.
- The present invention intends to propose solutions for treating various ophthalmic or ocular conditions and diseases. The present invention is especially designed for the treatment of posterior ocular conditions, which means any disease, ailment or condition which primarily affects or involves a posterior ocular site such as choroid or sclera (in a position posterior to a plane through the posterior wall of the lens capsule), vitreous, vitreous chamber, retina, optic nerve (including the optic disc), and blood vessels and nerves which vascularize or innervate a posterior ocular site. A posterior ocular condition can include a disease, ailment or condition. Examples of such conditions include without limitation Macular Disorders such as myopia, Non-Exudative Age Related Macular Degeneration (Dry), Exudative Age Related Macular Degeneration (Wet), Choroidal Neovascular Membranes (others than ARMD) and Cystoid Macular Edema; Inflammatory Disorders such as Uveitic Retinal Disease, Endophthalmitis, Toxoplasmic Retinochoroiditis, Systemic General Disorders Associated with Retinal Uveitis or Retinochoroidal Syndromes (Syphilis, Tuberculosis, Lyme Diseases, Chung Strauss Disease, LED, etc), Neuroretinitis, Optic Neuritis; Vascular Disorders such as Diabetic Retinopathy (all stages), Diabetic Macular Edema, Arterial Occlusion, Venous Occlusion; Heredo Retinal Dystrophies such as Stargardt's Disease, Fundus Flavimaculatus, other Heredomacular Dysropy; Trauma caused by Laser, photodynamic therapy, Photocoagulation, Hypoperfusion During Surgery; Macular Hole; Retinal Disease Associated with Tumors, Posterior Uveal Melanoma, Retinoblastoma and Choroidal Metastasis
- As used herein, “effective amount,” and “sufficient amount” may be used interchangeably and refer to an amount of an ingredient which is sufficient to achieve an intended physiological effect. Thus, a “therapeutically effective amount” refers to a non-toxic, but sufficient amount of an active agent, to achieve therapeutic results in treating a condition for which the active agent is known to be effective. The determination of an effective amount is well within the ordinary skill in the art of pharmaceutical sciences and medicine, in that it may depend on various biological factors or individual variation and response to treatments.
- As used herein, “subject” refers to a mammal that may benefit from the administration of a composition or method as recited herein. Most often, the subject will be a human but can be of any animals.
- As used herein, “about” means approximately or nearly and in the context of a numerical value or range set forth herein means .+−.10% of the numerical value or range recited or claimed.
- As used herein, “administration,” and “administering” refer to the manner in which a prodrug is presented to a subject.
- As used herein, “invasive” refers to a form of administration that ruptures or punctures a biological membrane or structure with a mechanical means across which a prodrug is being delivered.
- As used herein, “active agent” or “drug” may be used interchangeably to refer to an agent or substance that has measurable specified or selected physiologic activity when administered to a subject in a significant or effective amount. Examples of drugs useful in the present invention include without limitation: antivirals, chosen from the group comprising idoxuridine, trifluorothymidine, trifluorouridine, acyclovir, ganciclovir, cidofovir, interferon, DDI, AZT, foscamet, vidarabine, irbavirin; non-steroidal anti-inflammatories chosen from the group comprising amfenac, ketorolac, indomethacin, ibuprofen, diclofenac, flurbiprofen, piroxicam and other COX2 inhibitors; cytokines, interleukines and growth factors epidermal growth factor, fibroblast growth factor, pigment epithelium growth factor, platelet derived growth factor, transforming growth factor beta, ciliary neurotrophic growth factor, glial derived neurotrophic factor, NGF, EPO, PLGF, brain nerve growth factor (BNGF), vascular endothelial growth factor (VEGF) and monoclonal antibodies or proteins inhibiting the activity of such cytokines and growth factors; anti-inflammatories chosen from the group comprising alclometasone, amcinonide, amcinafel, amcinafide, beclamethasone, betamethasone, clobetasone, chloroprednisone, clocortelone, cortisol, C21-des-methylpropionyl-ciclesonide, cortodoxone, difluorosone, descinolone, desonide, defluprednate, dihydroxycortisone, desoximetasone, dexamethasone, deflazacort, diflorasone, dichlorisone, fluazacort, flucetonide, flucloronide, fludrotisone, fluorocortisone, flumethasone, flunisolide, fluocinonide, fluocinolone, flucortolone, fluperolone, fluprednisolone, fluroandrenolone, flurandrenolide, fluorametholone, fluticasone, hydrocortisone, hydrocortamate, loteprendol, medrysone, meprednisone, methylprednisone, methylprednisolone, mometasone, paramethasone, prednisolone, and triamcinolone, salts, derivatives, and a mixture thereof; antiangiogenic compounds such as anecortave, combretastatin, vascular endothelial growth factor (VEGF) inhibitors, squalamine, AdPEDF, VEGF-traps; immunological response modifiers chosen from the group comprising mycophenolic acid, muramyl dipeptide, cyclosporins, interferons, interleukin-2, cytokines, tacrolimus, tumor necrosis factor, pentostatin, thymopentin, transforming factor beta.sub.2, erythropoetin; antineogenesis proteins; antibodies (monoclonal or polyclonal) or antibodies fragments, oligoaptamers, aptamers and gene fragments (oligonucleotides, plasmids, ribozymes, small interference RNA (SiRNA), nucleic acid fragments, peptides).
- According to an embodiment of the invention, the drug has an ophthalmic physiologic therapeutic activity, whereas the prodrug is inactive.
- According to another embodiment of the invention the prodrug is a drug, or is prepared from a drug, which has or was grafted with functional groups such as haloformyl, hydroxyl, aldehyde, alkyl, alkenyl, alkynyl, carboxamide, primary amine, secondary amine, tertiary amine, quaternary ammonium ion, azo (Diimide), benzyl, carboxylate, carboxyl, cyanate, thiocyanate, ether, ester, halo, primary ketimine, secondary ketimine, primary aldimine, secondary aldimine, isocyanide, isocyanate, isothiocyanate, ketone, nitrile, nitro, nitroso, peroxy, phenyl, phosphino, phosphate, phosphono, phosphate, pyridyl, sulfonyl, sulfo, sulfinyl or sulfhydryl groups.
- As used herein, “prodrug” refers to a drug precursors which following administration, release the drug in vivo via some chemical or physiological process. According to an embodiment of the invention, the prodrug is inactive. According to an embodiment of the invention the prodrug releases the drug by a biological reaction, such as enzymatic cleavage. The prodrug is a composition including the pro-active ingredient, eventually in combination with any suitable excipient, especially any excipient injectable in the vitreous body of the eye. The term composition should not be construed as an implantable device.
- According to an embodiment of the invention, the enzyme involved in the transformation of the prodrug into the drug may be:
- Oxidoreductases acting on the CH, CH2, CH—OH, aldehyde, oxo, CH—CH, CH—NH2, CH—NH, sulfur, phosphorus, arsenic or heme groups of donors; oxidoreductases acting on NADH or NADPH; oxidoreductases acting on nitrogenous compounds, diphenols and related substances or hydrogen as donors; oxygenases; oxidoreductases acting on peroxide or superoxide radicals as acceptors; oxidoreductases acting on the iron-sulfur proteins as donors;
- Transferases transferring one carbon, alkyl, aryl, nitrogenous, aldehyde or ketone groups; transferases; acyltransferases; glycosyltransferases; transferases transferring phosphorus-, selenium- or sulfur-containing groups;
- Lyases such as carbon-carbon, carbon-oxygen, carbon-nitrogen, carbon-sulfur, carbon-halide or phosphorus-oxygen lyases;
- Isomerases such as racemases and epimerases; intramolecular oxidoreductases; intramolecular transferases or intramolecular lyases;
- Ligases forming carbon-oxygen, carbon-sulfur, carbon-nitrogen, carbon-carbon, phosphoric ester or nitrogen-metal bonds.
- Preferred enzymes are hydrolases which act on ester or ether bonds; hydrolases acting on carbon-nitrogen, carbon-carbon, halide, phosphorus-nitrogen, sulfur-nitrogen, carbon-phosphorus, sulfur-sulfur or carbon-sulfur bonds; glycosylases; peptidases; hydrolases acting on acid anhydrides.
- Preferred prodrugs are esters of drugs, wherein the ester group is of formula —COOR, or ether of drugs wherein the ester group is of formula OR, wherein R is a long alkyl chain, preferably a C4-C16 alkyl chain, more preferably any suitable lipophilic chain.
- As used herein, alkyl means straight chain saturated hydrocarbon or branched saturated hydrocarbon. Preferred alkyl groups are those comprising more than 4 carbon atoms, preferentially more than 8 atoms, more preferentially more than 12 atoms.
- The invention is further illustrated by the following example, which should not be considered in any way as a limitation the scope of the protection.
- A liquid chromatographic-mass spectrometric method for the simultaneous determination of dexamethasone and dexamethasone palmitate in ocular tissues was developed. Analytes and internal standard (roxithromycine) were extracted from the tissues using acetonitrile and separated by reverse phase liquid chromatography with a C8 column and a gradient mobile phase. The compounds were detected by mass spectrometric detection (atmospheric pressure ionization) with selected ion monitoring (SIM) (393.0 for dexamethasone and 631.5 for dexamethasone palmitate). The method was selective for both compounds and the limits of quantification were 32.7 ng/g of retina and 71.6 ng/g choroid. The unweighed linear model was applied.
- One single unilateral injection of a 0.8% (8 mg/ml) dexamethasone palmitate emulsion was administered intravitreally (100 μL) to rabbits. Animals were sacrificed at days 1, 7, 14, 21, 28 or 60 days (n=4/timepoint). Dexamethasone (D) and dexamethasone palmitate (DP) in tissues were determined. All concentrations are expressed in ng/g
-
-
Day 1 Day 7 Day 14 Day 28 Day 60 Mean sd Mean sd Mean sd Mean sd Mean sd Retina DP 106 74 93 38 136 19 146 109 55 37 (nmol/g) D 7 2 11 4 6 4 4 1 2 2 (nmol/g) DP/P 15.14 8.45 22.6 36.5 0.036 Choroid DP 191 69 103 77 22 11 143 61 52 22 (nmol/g) D 12 6 12 7 9 4 4.2 1 3 2 (nmol/g) DP/P 15.91 8.58 2.44 35.65 17.33 Aqueous DP ND ND ND ND ND ND ND ND 0 0 humor (nmol/g) D ND ND ND ND ND ND ND ND 0 1 (nmol/g) ND: Not determined. - Following IVT injection of a dose of 800 μg of prodrug, dexamethasone therapeutic levels of about 1000 ng/g were maintained for at least 2 months in the target tissues. Moreover, considerable amounts of the prodrug dexapalmitate remained in both retina and choroid, indicating an even more long-lasting release.
- At the same time, the amounts of steroid in the vitreous and plasma were undetectable, suggesting fewer (if any) side effects in adjacent sites. This last fact was corroborated by IOP measurements, which were normal 2 months following the injection.
Claims (15)
1. A method for treating an ocular disease affecting the posterior segment of the eye, in a subject in need thereof, comprising administering to said subject an effective amount of prodrug wherein the prodrug is a composition injected into the vitreous body, and the frequency of injections does not exceed one injection per month.
2. The method according to claim 1 , wherein two months after one injection of said prodrug; the drug cannot be detected in the vitreous or the molar ratio of the prodrug to the drug, in the vitreous, is more than 60.
3. The method according to claim 1 , wherein the molar ratio of the prodrug to the drug, in the retina, two months after one injection of said prodrug, is less than 60.
4. The method according to claim 1 , wherein the molar ratio of the prodrug to the drug, in the choroid, two months after one injection of said prodrug, is less than 60.
5. The method according to claim 1 , wherein the prodrug is injected in the vitreous in an amount enabling the sustained release of a therapeutically amount of said drug for a duration of at least one month, preferably at least 2 months, more preferably at least 6 months.
6. The method according to claim 1 , wherein the prodrug is injected at most once every two months, more preferably at most once every six months.
7. The method according to claim 1 , wherein the half-life of the prodrug is of at least 15 days.
8. The method according to claim 1 , wherein the prodrug is dexamethasone palmitate.
9. The method according to claim 1 , wherein the prodrug is in combination with any suitable excipient or carrier suitable for ophthalmic use.
10. The method according to claim 1 wherein the prodrug is within an oily carrier.
11. The method according to claim 1 wherein the prodrug is within an emulsion.
12. The method according to claim 1 , wherein the prodrug releases at least one drug selected in the group comprising antivirals, chosen from the group comprising idoxuridine, trifluorothymidine, trifluorouridine, acyclovir, ganciclovir, cidofovir, interferon, DDI, AZT, foscamet, vidarabine, irbavirin; non-steroidal anti-inflammatories chosen from the group comprising amfenac, ketorolac, indomethacin, ibuprofen, diclofenac, flurbiprofen, piroxicam and other COX2 inhibitors; cytokines, interleukines and growth factors epidermal growth factor, fibroblast growth factor, pigment epithelium growth factor, platelet derived growth factor, transforming growth factor beta, ciliary neurotrophic growth factor, glial derived neurotrophic factor, NGF, EPO, PLGF, brain nerve growth factor (BNGF), vascular endothelial growth factor (VEGF) and monoclonal antibodies or proteins inhibiting the activity of such cytokines and growth factors; anti-inflammatories chosen from the group comprising alclometasone dipropionate, amcinonide, amcinafel, amcinafide, beclamethasone, betamethasone, betamethasone dipropionate, betamethasone valerate, clobetasone propionate, chloroprednisone, clocortelone, Cortisol, cortisone, cortodoxone, difluorosone diacetate, descinolone, desonide, defluprednate, dihydroxycortisone, desoximetasone, dexamethasone, deflazacort, diflorasone, diflorasone diacetate, dichlorisone, esters of betamethasone, fluazacort, flucetonide, flucloronide, fludrotisone, fluorocortisone, flumethasone, flunisolide, fluocinonide, fluocinolone, fluocinolone acetonide, flucortolone, fluperolone, fluprednisolone, fluroandrenolone acetonide, fluocinolone acetonide, flurandrenolide, fluorametholone, fluticasone propionate, hydrocortisone, hydrocortisone butyrate, hydrocortisone valerate, hydrocortamate, loteprendol, medrysone, meprednisone, methylprednisone, methylprednisolone, mometasone furoate, paramethasone, paramethasone acetate, prednisone, prednisolone, prednidone, triamcinolone acetonide, triamcinolone hexacatonide, and triamcinolone, salts, derivatives, and a mixture thereof; antiangiogenic compounds such as anecortave, combretastatin, vascular endothelial growth factor (VEGF) inhibitors, squalamine, AdPEDF, VEGF-traps; immunological response modifiers chosen from the group comprising muramyl dipeptide, cyclosporins, interferons, interleukin-2, cytokines, tacrolimus, tumor necrosis factor, pentostatin, thymopentin, transforming factor beta.sub.2, erythropoetin; antineogenesis proteins; antibodies (monoclonal or polyclonal) or antibodies fragments, oligoaptamers, aptamers and gene fragments such as oligonucleotides, plasmids, ribozymes, small interference RNA, (nucleic acid fragments, peptides.
13. The method according to claim 1 , wherein the treatment or prevention of a disorder affecting the posterior segment of the eye,comprises the treatment of any disease, ailment or condition which primarily affects or involves a posterior ocular site such as choroid or sclera, vitreous, vitreous chamber, retina, optic nerve, and blood vessels and nerves which vascularize or innervate a posterior ocular site.
14. The method according to any one of claim 1 , wherein the disorder is one or more of the following: Macular Disorders such as myopia, Non-Exudative Age Related Macular Degeneration, Exudative Age Related Macular Degeneration, Choroidal Neovascular Membranes and Cystoid Macular Edema; Inflammatory Disorders such as Uveitic Retinal Disease, Endophthalmitis, Toxoplasmic Retinochoroiditis, Systemic General Disorders Associated with Retinal Uveitis or Retinochoroidal Syndromes (Syphilis, Tuberculosis, Lyme Diseases, Chung Strauss Disease, LED, etc), Neuroretinitis, Optic Neuritis; Vascular Disorders such as Diabetic Retinopathy, Diabetic Macular Edema, Arterial Occlusion, Venous Occlusion; Heredo Retinal Dystrophies such as Stargardt's Disease, Fundus Flavimaculatus, other Heredomacular Dysropy; Trauma caused by Laser, photodynamic therapy, Photocoagulation, Hypoperfusion During Surgery; Macular Hole; Retinal Disease Associated with Tumors, Posterior Uveal Melanoma, Retinoblastoma and Choroidal Metastasis.
15. A method to extend the duration of a treatment of a disease or a condition of the posterior segment of an eye, in a subject in need thereof, comprising administering to said subject an effective amount of a prodrug wherein said prodrug is injected into the vitreous body at most one a month.
Priority Applications (29)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10177375.2A EP2322183B1 (en) | 2006-06-01 | 2006-06-01 | Use of prodrugs for ocular intravitreous administration |
DK10177382.8T DK2319517T3 (en) | 2006-06-01 | 2006-06-01 | APPLICATION OF PRODRUGS TO OCULAR, INTRAVENOUS ADMINISTRATION |
SI200631521T SI1864668T1 (en) | 2006-06-01 | 2006-06-01 | Use of prodrugs for ocular intravitreous administration |
PT62909023T PT1864668E (en) | 2006-06-01 | 2006-06-01 | Use of prodrugs for ocular intravitreous administration |
PL10177375T PL2322183T3 (en) | 2006-06-01 | 2006-06-01 | Use of prodrugs for ocular intravitreous administration |
PL10177382T PL2319517T3 (en) | 2006-06-01 | 2006-06-01 | Use of prodrugs for ocular intravitreous administration |
PT62909015T PT1864667E (en) | 2006-06-01 | 2006-06-01 | Use of prodrugs for ocular intravitreous administration |
EP06290901.5A EP1864667B1 (en) | 2006-06-01 | 2006-06-01 | Use of prodrugs for ocular intravitreous administration |
EP10177382.8A EP2319517B1 (en) | 2006-06-01 | 2006-06-01 | Use of prodrugs for ocular intravitreous administration |
PL06290902T PL1864668T3 (en) | 2006-06-01 | 2006-06-01 | Use of prodrugs for ocular intravitreous administration |
US11/444,349 US20070280902A1 (en) | 2006-06-01 | 2006-06-01 | Method for treating eye disease or conditions affecting the posterior segment of the eye |
DK06290902.3T DK1864668T3 (en) | 2006-06-01 | 2006-06-01 | APPLICATION OF PRODRUG FOR OCULAR, INTRAVITREAL ADMINISTRATION |
US11/444,337 US20070281914A1 (en) | 2006-06-01 | 2006-06-01 | Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye |
ES06290902T ES2399976T3 (en) | 2006-06-01 | 2006-06-01 | Use of prodrugs for ocular intravitreal administration |
PL06290901T PL1864667T3 (en) | 2006-06-01 | 2006-06-01 | Use of prodrugs for ocular intravitreous administration |
EP06290902A EP1864668B1 (en) | 2006-06-01 | 2006-06-01 | Use of prodrugs for ocular intravitreous administration |
CN2007800201723A CN101553235B (en) | 2006-06-01 | 2007-06-01 | Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye |
AU2007267079A AU2007267079B2 (en) | 2006-06-01 | 2007-06-01 | Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye |
PCT/EP2007/055413 WO2007138113A1 (en) | 2006-06-01 | 2007-06-01 | Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye |
US11/806,556 US9192567B2 (en) | 2006-06-01 | 2007-06-01 | Method for treating eye disease or conditions affecting the posterior segment of the eye |
KR1020087031197A KR101408317B1 (en) | 2006-06-01 | 2007-06-01 | Use of a Steroid Prodrug for the Treatment of Disease of the Posterior Segment of the Eye |
CA2653902A CA2653902C (en) | 2006-06-01 | 2007-06-01 | Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye |
JP2009512617A JP5284953B2 (en) | 2006-06-01 | 2007-06-01 | Prodrug for intravitreal injection |
JP2009512616A JP5455624B2 (en) | 2006-06-01 | 2007-06-01 | Use of steroid prodrugs to treat posterior eye diseases |
US11/806,554 US8227452B2 (en) | 2006-06-01 | 2007-06-01 | Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye |
PCT/EP2007/055414 WO2007138114A1 (en) | 2006-06-01 | 2007-06-01 | Use of prodrugs for ocular intravireous administration |
HK08104425.9A HK1110219A1 (en) | 2006-06-01 | 2008-04-21 | Use of prodrugs for ocular intravitreous administration |
HK08104540.9A HK1110221A1 (en) | 2006-06-01 | 2008-04-23 | Use of prodrugs for ocular intravitreous administration |
IL195626A IL195626A (en) | 2006-06-01 | 2008-12-01 | Use of an ophthalmic composition comprising at least one prodrug in combination with any ophthalmically acceptable carrier for the preparation of a medicament for the treatment of an ocular condition or disease of the interior of the eye of a human being or an animal |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06290901.5A EP1864667B1 (en) | 2006-06-01 | 2006-06-01 | Use of prodrugs for ocular intravitreous administration |
EP06290902A EP1864668B1 (en) | 2006-06-01 | 2006-06-01 | Use of prodrugs for ocular intravitreous administration |
US11/444,337 US20070281914A1 (en) | 2006-06-01 | 2006-06-01 | Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye |
US11/444,349 US20070280902A1 (en) | 2006-06-01 | 2006-06-01 | Method for treating eye disease or conditions affecting the posterior segment of the eye |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/806,556 Division US9192567B2 (en) | 2006-06-01 | 2007-06-01 | Method for treating eye disease or conditions affecting the posterior segment of the eye |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070280902A1 true US20070280902A1 (en) | 2007-12-06 |
Family
ID=39712456
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/444,337 Abandoned US20070281914A1 (en) | 2006-06-01 | 2006-06-01 | Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye |
US11/444,349 Abandoned US20070280902A1 (en) | 2006-06-01 | 2006-06-01 | Method for treating eye disease or conditions affecting the posterior segment of the eye |
US11/806,554 Active 2028-03-03 US8227452B2 (en) | 2006-06-01 | 2007-06-01 | Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye |
US11/806,556 Expired - Fee Related US9192567B2 (en) | 2006-06-01 | 2007-06-01 | Method for treating eye disease or conditions affecting the posterior segment of the eye |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/444,337 Abandoned US20070281914A1 (en) | 2006-06-01 | 2006-06-01 | Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/806,554 Active 2028-03-03 US8227452B2 (en) | 2006-06-01 | 2007-06-01 | Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye |
US11/806,556 Expired - Fee Related US9192567B2 (en) | 2006-06-01 | 2007-06-01 | Method for treating eye disease or conditions affecting the posterior segment of the eye |
Country Status (15)
Country | Link |
---|---|
US (4) | US20070281914A1 (en) |
EP (4) | EP2319517B1 (en) |
JP (2) | JP5455624B2 (en) |
KR (1) | KR101408317B1 (en) |
CN (1) | CN101553235B (en) |
AU (1) | AU2007267079B2 (en) |
CA (1) | CA2653902C (en) |
DK (2) | DK2319517T3 (en) |
ES (1) | ES2399976T3 (en) |
HK (2) | HK1110219A1 (en) |
IL (1) | IL195626A (en) |
PL (4) | PL2319517T3 (en) |
PT (2) | PT1864667E (en) |
SI (1) | SI1864668T1 (en) |
WO (2) | WO2007138113A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10463609B2 (en) * | 2007-10-05 | 2019-11-05 | Wayne State University | Dendrimers for sustained release of compounds |
US11918657B2 (en) | 2017-11-10 | 2024-03-05 | The Johns Hopkins University | Dendrimer delivery system and methods of use thereof |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2319517T3 (en) | 2006-06-01 | 2014-01-31 | Santen Sas | Use of prodrugs for ocular intravitreous administration |
WO2009071594A1 (en) * | 2007-12-04 | 2009-06-11 | Novagali Pharma Sa | Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders |
AU2009246520B2 (en) | 2008-05-12 | 2012-04-19 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
UA116622C2 (en) * | 2011-11-11 | 2018-04-25 | Аллерган, Інк. | 4-pregenen-11ss-17-21-triol-3,20-dione derivatives for the treatment of ocular conditions |
WO2013119988A1 (en) * | 2012-02-10 | 2013-08-15 | Taiwan Liposome Company, Ltd | Pharmaceutical compositions to reduce complications of ocular steroid |
CN110944668A (en) | 2017-06-16 | 2020-03-31 | 学校法人同志社 | Medicament comprising an mTOR inhibitor for treating or preventing ocular symptoms, disorders or diseases and uses thereof |
CN111068071A (en) * | 2018-10-22 | 2020-04-28 | 武汉纽福斯生物科技有限公司 | Gene therapy for Leber genetic optic neuropathy |
EP3871662B1 (en) * | 2020-02-25 | 2023-06-07 | Labomed Pharmaceutical Company S.A. | Oral solutions comprising fludrocortisone acetate |
JP2023542435A (en) | 2020-09-16 | 2023-10-06 | サンテン エスエーエス | Oil-in-water emulsions for intravitreal administration |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060073182A1 (en) * | 2004-10-01 | 2006-04-06 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS609726B2 (en) * | 1980-05-15 | 1985-03-12 | 株式会社 ミドリ十字 | steroid preparations |
JPS5716818A (en) | 1981-04-25 | 1982-01-28 | Green Cross Corp:The | Steroid fatty emulsion |
AU531588B2 (en) | 1981-08-17 | 1983-09-01 | Yoshitomi Pharmaceutical Industries, Ltd. | Emulsifying water-insoluble steroid |
EP0244178A3 (en) * | 1986-04-28 | 1989-02-08 | Iolab, Inc | Intraocular dosage compositions and method of use |
AU4201189A (en) | 1988-08-26 | 1990-03-23 | Alcon Laboratories, Inc. | Combination of quinolone antibiotics and steroids for topical ophthalmic use |
JPH05132498A (en) * | 1991-11-08 | 1993-05-28 | Asahi Glass Co Ltd | Steroid derivative and its pharmaceutical preparation |
IL101241A (en) | 1992-03-16 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier |
CA2125060C (en) * | 1993-07-02 | 1999-03-30 | Henry P. Dabrowski | Ophthalmic solution for artificial tears |
ES2156156T3 (en) * | 1993-08-02 | 2001-06-16 | Commw Scient Ind Res Org | THERAPEUTIC COMPOUND - FATTY ACID CONJUGATES. |
ES2094688B1 (en) | 1994-08-08 | 1997-08-01 | Cusi Lab | MANOEMULSION OF THE TYPE OF OIL IN WATER, USEFUL AS AN OPHTHALMIC VEHICLE AND PROCEDURE FOR ITS PREPARATION. |
JP3410364B2 (en) | 1997-05-14 | 2003-05-26 | 千寿製薬株式会社 | Difluprednate-containing composition |
US6114319A (en) | 1997-05-14 | 2000-09-05 | Senju Pharmaceutical Co., Ltd. | Compositions containing difluprednate |
IL121647A (en) * | 1997-08-28 | 2001-07-24 | Pharmateam Dev Ltd | Pharmaceutical compositions for the treatment of ocular inflammation comprising dexamethasone palmitate |
EP1020194A4 (en) | 1997-10-01 | 2003-05-21 | Wakamoto Pharma Co Ltd | O/w emulsion compositions |
JP2000212067A (en) * | 1999-01-19 | 2000-08-02 | Towa Yakuhin Kk | Emulsion preparation including medicinal substance |
IL161588A0 (en) | 2001-11-01 | 2004-09-27 | Yissum Res Dev Co | Method and composition for dry eye treatment |
WO2004058272A1 (en) * | 2002-12-20 | 2004-07-15 | Control Delivery Systems, Inc. | Steroid compositions for intraocular use |
US20050009910A1 (en) * | 2003-07-10 | 2005-01-13 | Allergan, Inc. | Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug |
EP2036548A1 (en) * | 2003-09-22 | 2009-03-18 | onepharm Research & Development GmbH | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss |
US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
EP1611879B1 (en) * | 2004-07-02 | 2009-08-12 | Novagali Pharma SA | Use of emulsions for intra- and periocular injection |
BRPI0513243B8 (en) * | 2004-07-12 | 2021-05-25 | Allergan Inc | ophthalmic compositions and their uses |
US20060094700A1 (en) * | 2004-11-02 | 2006-05-04 | Allergan, Inc. | Heat sterilization of a steroid in the presence of phosphate |
CA2586074C (en) * | 2004-11-09 | 2013-07-23 | Novagali Pharma Sa | Ophthalmic oil-in-water type emulsion with stable positive zeta potential |
CN1905012A (en) | 2005-07-31 | 2007-01-31 | 新科实业有限公司 | Magnetic head flap combination with microdriver and magnetic disk driver thereof |
US8109884B2 (en) * | 2005-09-23 | 2012-02-07 | Kitchener Clark Wilson | Dynamic metabolism monitoring system |
PL2319517T3 (en) | 2006-06-01 | 2014-01-31 | Santen Sas | Use of prodrugs for ocular intravitreous administration |
-
2006
- 2006-06-01 PL PL10177382T patent/PL2319517T3/en unknown
- 2006-06-01 PL PL06290901T patent/PL1864667T3/en unknown
- 2006-06-01 EP EP10177382.8A patent/EP2319517B1/en active Active
- 2006-06-01 EP EP06290901.5A patent/EP1864667B1/en active Active
- 2006-06-01 EP EP06290902A patent/EP1864668B1/en active Active
- 2006-06-01 PL PL06290902T patent/PL1864668T3/en unknown
- 2006-06-01 PT PT62909015T patent/PT1864667E/en unknown
- 2006-06-01 SI SI200631521T patent/SI1864668T1/en unknown
- 2006-06-01 ES ES06290902T patent/ES2399976T3/en active Active
- 2006-06-01 PT PT62909023T patent/PT1864668E/en unknown
- 2006-06-01 PL PL10177375T patent/PL2322183T3/en unknown
- 2006-06-01 DK DK10177382.8T patent/DK2319517T3/en active
- 2006-06-01 EP EP10177375.2A patent/EP2322183B1/en active Active
- 2006-06-01 US US11/444,337 patent/US20070281914A1/en not_active Abandoned
- 2006-06-01 DK DK06290902.3T patent/DK1864668T3/en active
- 2006-06-01 US US11/444,349 patent/US20070280902A1/en not_active Abandoned
-
2007
- 2007-06-01 CA CA2653902A patent/CA2653902C/en not_active Expired - Fee Related
- 2007-06-01 WO PCT/EP2007/055413 patent/WO2007138113A1/en active Application Filing
- 2007-06-01 US US11/806,554 patent/US8227452B2/en active Active
- 2007-06-01 WO PCT/EP2007/055414 patent/WO2007138114A1/en active Application Filing
- 2007-06-01 JP JP2009512616A patent/JP5455624B2/en not_active Expired - Fee Related
- 2007-06-01 AU AU2007267079A patent/AU2007267079B2/en not_active Ceased
- 2007-06-01 CN CN2007800201723A patent/CN101553235B/en not_active Expired - Fee Related
- 2007-06-01 KR KR1020087031197A patent/KR101408317B1/en active IP Right Grant
- 2007-06-01 JP JP2009512617A patent/JP5284953B2/en not_active Expired - Fee Related
- 2007-06-01 US US11/806,556 patent/US9192567B2/en not_active Expired - Fee Related
-
2008
- 2008-04-21 HK HK08104425.9A patent/HK1110219A1/en not_active IP Right Cessation
- 2008-04-23 HK HK08104540.9A patent/HK1110221A1/en not_active IP Right Cessation
- 2008-12-01 IL IL195626A patent/IL195626A/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060073182A1 (en) * | 2004-10-01 | 2006-04-06 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10463609B2 (en) * | 2007-10-05 | 2019-11-05 | Wayne State University | Dendrimers for sustained release of compounds |
US11684569B2 (en) | 2007-10-05 | 2023-06-27 | Wayne State University | Dendrimers for sustained release of compounds |
US11918657B2 (en) | 2017-11-10 | 2024-03-05 | The Johns Hopkins University | Dendrimer delivery system and methods of use thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070280902A1 (en) | Method for treating eye disease or conditions affecting the posterior segment of the eye | |
US8623852B2 (en) | Topical methods and compositions for the treatment of eye diseases and conditions | |
US9216106B2 (en) | Device and method for the delivery of drugs for the treatment of posterior segment disease | |
JP2006518382A (en) | Use of steroids to treat people suffering from eye disorders | |
DK2322183T3 (en) | The use of pro-drugs for ocular administration, intravitreal | |
ES2437160T3 (en) | Use of prodrugs for ocular intravitreal administration | |
KR101541416B1 (en) | Use of a Steroid Prodrug for the Treatment of Disease of the Posterior Segment of the Eye | |
Biopharma | Lambert et al. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NOVAGALI PHARMA SA, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RABINOVICH-GUILATT, LAURA;LAMBERT, GREGORY;REEL/FRAME:018067/0404 Effective date: 20060721 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |